Description

12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3 -[[4-[3-(4-morpholinyl)propoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)- , 1,1-dimethylethyl ester, [3S-(3R*,4S*,8S*,9R*)]- is a complex, stereochemically defined organic compound that serves as a critical advanced pharmaceutical intermediate or building block in modern synthetic chemistry. Its intricate molecular architecture, featuring oxa- and triaza- heterocyclic motifs, makes it highly valuable for constructing sophisticated active pharmaceutical ingredients (APIs). This compound is primarily sought by research organizations and pharmaceutical manufacturers engaged in the development of novel therapeutic agents, particularly in areas requiring high-precision molecular scaffolds.

Application

• Pharmaceutical Intermediate: Key building block in the multi-step synthesis of complex drug candidates, particularly for oncology, antiviral, or central nervous system (CNS) targeted therapies.
• Medicinal Chemistry Research: Used in research and development (R&D) for structure-activity relationship (SAR) studies and lead optimization processes.
• Process Chemistry Development: Serves as a defined intermediate for scaling up and optimizing synthetic routes under Good Manufacturing Practice (GMP) conditions.
• Custom Synthesis & Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of bespoke molecules for clinical trials.
• Bioconjugation & Prodrug Synthesis: Potential utility in creating targeted drug delivery systems or prodrug formulations due to its functional group richness.

Basic Information

Product Name	12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3 -[[4-[3-(4-morpholinyl)propoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)- , 1,1-dimethylethyl ester, [3S-(3R*,4S*,8S*,9R*)]-
CAS No.	162539-73-3
Molecular Formula	C41H61N4O8
Molecular Weight	737.95 g/mol
Synonyms	tert-Butyl (3S,4S,8S,9R)-4,8-dihydroxy-13,13-dimethyl-3-[[4-[3-(4-morpholinyl)propoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)-12-oxa-2,6,10-triazatetradecanoate; UNII-8V5Y1B6F34; 8V5Y1B6F34; BMS-232632 Intermediate; Atazanavir Sulfate Intermediate; [3S-(3R*,4S*,8S*,9R*)]-4,8-Dihydroxy-13,13-dimethyl-3-[[4-[3-(4-morpholinyl)propoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)-12-oxa-2,6,10-triazatetradecanoic Acid 1,1-Dimethylethyl Ester; (3S,4S,8S,9R)-tert-Butyl 4,8-dihydroxy-13,13-dimethyl-3-((4-(3-morpholinopropoxy)benzyl)-11-oxo-9-benzyl-12-oxa-2,6,10-triazatetradecanoate
EINECS	Contact for details

Quality Control

This high-value intermediate is produced and controlled under a rigorous quality management system. Each batch is subjected to comprehensive analytical testing including HPLC for purity and chiral integrity, NMR for structural confirmation, and residual solvent analysis to ensure it meets stringent specifications for pharmaceutical use. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting compliance with agreed-upon standards. Our facilities and processes are designed to support development from non-GMP research quantities through to GMP-grade material for clinical supply.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider using desiccants or storing under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Heavy Metals	< 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.